Autoantibodies neutralizing type I IFNs are present in

Authors

Paul Bastard
Adrian Gervais
Tom Le Voyer
Jérémie Rosain
Quentin Philippot
Jérémy Manry
Eleftherios Michailidis
Hans-Heinrich Hoffmann
Shohei Eto
Marina Garcia-Prat
Lucy Bizien
Alba Parra-Martínez
Rui Yang
Liis Haljasmägi
Mélanie Migaud
Karita Särekannu
Julia Maslovskaja
Nicolas de Prost
Yacine Tandjaoui-Lambiotte
Charles-Edouard Luyt
Blanca Amador-Borrero
Alexandre Gaudet
Julien Poissy
Pascal Morel
Pascale Richard
Fabrice Cognasse
Jesus Troya
Sophie Trouillet-Assant
Alexandre Belot
Kahina Saker
Pierre Garçon
Jacques G Rivière
Jean-Christophe Lagier
Stéphanie Gentile
Lindsey B Rosen
Elana Shaw
Tomohiro Morio
Junko Tanaka
David Dalmau
Pierre-Louis Tharaux
Damien Sene
Alain Stepanian
Bruno Megarbane
Vasiliki Triantafyllia
Arnaud Fekkar
James R Heath, Institute for Systems Biology, Seattle, WA 98109, USA
José Luis Franco
Juan-Manuel Anaya
Jordi Solé-Violán
Luisa Imberti
Andrea Biondi
Paolo Bonfanti
Riccardo Castagnoli
Ottavia M Delmonte
Yu Zhang
Andrew L Snow
Steven M Holland
Catherine Biggs
Marcela Moncada-Vélez
Andrés Augusto Arias
Lazaro Lorenzo
Soraya Boucherit
Boubacar Coulibaly
Dany Anglicheau
Anna M Planas
Filomeen Haerynck
Sotirija Duvlis
Robert L Nussbaum
Tayfun Ozcelik
Sevgi Keles
Ahmed A Bousfiha
Jalila El Bakkouri
Carolina Ramirez-Santana
Stéphane Paul
Qiang Pan-Hammarström
Lennart Hammarström
Annabelle Dupont
Alina Kurolap
Christine N Metz
Alessandro Aiuti
Giorgio Casari
Vito Lampasona
Fabio Ciceri
Lucila A Barreiros
Elena Dominguez-Garrido
Mateus Vidigal
Mayana Zatz
Diederik van de Beek
Sabina Sahanic
Ivan Tancevski
Yurii Stepanovskyy
Oksana Boyarchuk
Yoko Nukui
Miyuki Tsumura
Loreto Vidaur
Stuart G Tangye
Sonia Burrel
Darragh Duffy
Lluis Quintana-Murci
Adam Klocperk
Nelli Y Kann
Anna Shcherbina
Yu-Lung Lau
Daniel Leung
Matthieu Coulongeat
Julien Marlet
Rutger Koning
Luis Felipe Reyes
Angélique Chauvineau-Grenier
Fabienne Venet
Guillaume Monneret
Michel C Nussenzweig
Romain Arrestier
Idris Boudhabhay
Hagit Baris-Feldman
David Hagin
Joost Wauters
Isabelle Meyts
Adam H Dyer
Sean P Kennelly
Nollaig M Bourke
Rabih Halwani
Narjes Saheb Sharif-Askari
Karim Dorgham
Jérome Sallette
Souad Mehlal Sedkaoui
Suzan AlKhater
Raúl Rigo-Bonnin
Francisco Morandeira
Lucie Roussel
Donald C Vinh
Sisse Rye Ostrowski
Antonio Condino-Neto
Carolina Prando
Anastasiia Bonradenko
András N Spaan
Laurent Gilardin
Jacques Fellay
Stanislas Lyonnet
Kaya Bilguvar
Richard P Lifton
Shrikant Mane
HGID Lab
COVID Clinicians
COVID-STORM Clinicians
NIAID Immune Response to COVID Group
NH-COVAIR Study Group
Danish CHGE
Danish Blood Donor Study
St. James's Hospital
SARS CoV2 Interest group
French COVID Cohort Study Group
Imagine COVID-Group
Milieu Intérieur Consortium
CoV-Contact Cohort
Amsterdam UMC Covid-19
Biobank Investigators
COVID Human Genetic Effort
CONSTANCES cohort
3C-Dijon Study
Cerba Health-Care
Etablissement du Sang study group
Mark S Anderson
Bertrand Boisson
Vivien Béziat
Shen-Ying Zhang
Evangelos Vandreakos
Olivier Hermine
Aurora Pujol
Pärt Peterson
Trine H Mogensen
Lee Rowen, Institute for Systems Biology, Seattle, WA 98109, USA
James Mond
Stéphanie Debette
Xavier de Lamballerie
Xavier Duval
France Mentré
Marie Zins
Pere Soler-Palacin
Roger Colobran
Guy Gorochov
Xavier Solanich
Sophie Susen
Javier Martinez-Picado
Didier Raoult
Marc Vasse
Peter K Gregersen
Lorenzo Piemonti
Carlos Rodríguez-Gallego
Luigi D Notarangelo
Helen C Su
Kai Kisand
Satoshi Okada
Anne Puel
Emmanuelle Jouanguy
Charles M Rice
Pierre Tiberghien
Qian Zhang
Aurélie Cobat
Laurent Abel
Jean-Laurent Casanova

Document Type

Article

Publication Date

8-19-2021

Publication Title

Sci Immunol

Keywords

washington; seattle; isb

Abstract

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individualsyears, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.

Department

Infectious Diseases

Department

Institute for Systems Biology

Share

COinS